<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00259857</url>
  </required_header>
  <id_info>
    <org_study_id>5R01FD001847-05</org_study_id>
    <secondary_id>FDR00184705-83045-05</secondary_id>
    <nct_id>NCT00259857</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Alendronate (Fosamax) in Children With Osteoporosis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Prospective, Cross-Over Phase II Clinical Trial to Determine the Safety and Efficacy of Alendronate (Fosamax) in Juvenile Osteoporosis (IND#60,017)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FDA Office of Orphan Products Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We have previously evaluated the safety and efficacy of Alendronate in 10 patients with
      juvenile osteoporosis during a 12-month clinical trial. We have documented that Alendronate
      improved BMD of the spine and hip without any major side effects. There were no additional
      fractures during therapy. The present study is designed to further evaluate the safety and
      efficacy of Alendronate in 20 children with juvenile osteoporosis using a double-blind,
      randomized, placebo-controlled, cross-over protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoporosis is an uncommon disease in children and early adolescents. Patients have a low
      bone mineral density, develop fractures with minimal or no trauma, and frequently have a
      negative family history. The disease results from either diminished bone formation or
      increased bone removal (resorption). No specific drug therapy has been recommended for
      juvenile osteoporosis. Alendronate (Fosamax) is effective in inhibiting bone resorption,
      increasing BMD and reducing fractures in adults with postmenopausal osteoporosis, but have
      not become established therapies in children. In the present study, we plan to evaluate the
      safety and efficacy of Alendronate in 20 patients with juvenile osteoporosis in a two-year
      period. This is a randomized, double-blind, placebo-controlled protocol. In the year-1, 10
      patients will be assigned to receive Alendronate and 10 patients placebo. In the year-2,
      patients will be crossed over to the second arm of the study. Those who received Alendronate
      in the year-1, will receive placebo in the second year and vice verse. The patients will have
      5 visits, the initial screening visit followed by 4 post therapy visits in a six-month
      interval. Measurements include DXA bone density scan of spine and hip, urinalysis and blood
      work.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Improvement in Bone Mineral Density (BMD) of Spine After Therapy</measure>
    <time_frame>12 months therapy</time_frame>
    <description>Participants were screened for BMD of lumbar spine using DXA scan at visit 12 months after alendronate or placebo treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Improvement in Bone Mineral Density (BMD) of Spine After Therapy</measure>
    <time_frame>24 months therapy</time_frame>
    <description>BMD of lumbar spine was measured using DXA scan at visit 24 months (Year-2)after alendronate or placebo treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Improvement in Bone Mineral Density (BMD) of Hip After Therapy</measure>
    <time_frame>12 months of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Improvement in BMD of Hip</measure>
    <time_frame>24 months of therapy</time_frame>
    <description>Analysis was done per protocol and intention to treat.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Atraumatic Fractures</measure>
    <time_frame>0 months</time_frame>
    <description>Number of Participants with Atraumatic fractures before therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Atraumatic Fractures</measure>
    <time_frame>24 months</time_frame>
    <description>Number of participants with fractures at the completion of therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>1 Alendronate, Calcium, Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crossover study. Year-1, 10 participants will take study medication, calcium and vitamin D supplements and other 10 participants will take placebo, calcium and vitamin D supplements. Year-2, they will crossover to the second arm of the study. Those who took study medication and supplements in year-1, will take placebo and supplements in the year-2, and those 10 participants who took placebo and supplements in the year-1, will take study medications and supplements in the year-2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Placebo, Calcium and Vitamin D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Year-1, 10 participants will take Alendronate (study medication)and calcium and vitamin D supplement). Another 10 participants will take placebo, calcium and vitamin D. In year-2 they will crossover. Those who took alendronate in the first year, will take Placebo, calcium and vitamin D for 12 months and those who took Placebo in the first year, will take Alendronate, calcium and vitamin D in the second year (12 months).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
    <description>Group-1/Year-1:Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight, for 12 months. Group-1/Year-2:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-1:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-2: Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months.</description>
    <arm_group_label>1 Alendronate, Calcium, Vitamin D</arm_group_label>
    <arm_group_label>2 Placebo, Calcium and Vitamin D</arm_group_label>
    <other_name>Fosamax</other_name>
    <other_name>TUMS or Viactive</other_name>
    <other_name>Drisdol or Calciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility Criteria:

          -  5-15 yrs of age

          -  Weighing 20 kg and more

          -  History of multiple fractures

          -  Tanner stage II or less

          -  Osteoporosis by DXA.

        Inclusion Criteria:

          -  Male and female children with a history of one or more atraumatic fractures, or
             evidence of one or more compression fractures on radiographs of the spine (reduction
             of &gt;20 percent).

          -  Bone Mineral Density (BMD) determined by DXA sacn to confirm osteoporosis at a Z score
             greater than 2 SD (standard deviations) below the normal mean for age (Z score &lt; -2
             SD).

          -  Parental consent (and patient assent after age 12 years) to participate in the study.

          -  Sexual development at: Tanner stage II or less (Prepubertal stage).

          -  Weight = 20 kg and more.

        Exclusion Criteria:

          -  History of severe gastritis or reflux.

          -  Abnormalities of the esophagus that delay emptying, such as strictures or achalasia

          -  Marked kyphoscoliosis or the inability to sit or stand for at least 30 minutes

          -  Hypersensitivity to bisphosphonates

          -  Uncorrected hypocalcemia

          -  History of gastric or duodenal ulcers

          -  Renal dysfunction as indicated by serum Cr &gt;1.5 mg/dl.

          -  Liver dysfunction as indicated by serum SGPT &gt; 2 times the upper limit for age or
             serum total bilirubin &gt; 2.0 mg/dl.

          -  Diagnosis of osteogenesis imperfecta, a family history of osteogenesis imperfecta,
             blue sclerae or deafness.

          -  Diagnosis of active rickets or osteomalacia or serum bone alkaline phosphatase 2 times
             greater than normal for age.

          -  Pregnancy

          -  Anorexia Nervosa
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah A Bowlby, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.musckids.com/research/fosamax_trial.htm</url>
    <description>Medical University of South Carolina, Children's Hospital</description>
  </link>
  <results_reference>
    <citation>Key LL Jr, Ries W, Madyastha P, Reed F. Juvenile osteoporosis: recognizing the risk. J Pediatr Endocrinol Metab. 2003 May;16 Suppl 3:683-6.</citation>
    <PMID>12795371</PMID>
  </results_reference>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2005</study_first_submitted>
  <study_first_submitted_qc>November 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2005</study_first_posted>
  <results_first_submitted>November 9, 2010</results_first_submitted>
  <results_first_submitted_qc>December 29, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 19, 2011</results_first_posted>
  <last_update_submitted>December 29, 2010</last_update_submitted>
  <last_update_submitted_qc>December 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Deborah A Bowlby, MD, Assistant Professor</name_title>
    <organization>Medical University of South Carolina</organization>
  </responsible_party>
  <keyword>Fracture</keyword>
  <keyword>Bone Mineral Density</keyword>
  <keyword>DXA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Dates of recruitment period:O5/27/2004 to 02/01/2006. Types of location:outpatient clinic, Clinical and Translational Research Center (CTRC), Medical University of South Carolina, Charleston, South Carolina.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Gr-1:Yr-1/Yr-2: Alendronate/Pbo, Calcium, Vitamin D</title>
          <description>Group-1/Year-1, 11 participants will take Alendronate,(study medication) and calcium, and vitamin D (supplements) and in Year-2 they will crossover to placebo, calcium and vitamin D supplements.</description>
        </group>
        <group group_id="P2">
          <title>Gr-2:Yr-1/Yr-2: Pbo/Alendronate, Calcium and Vitamin D</title>
          <description>Group-2/Year-1, 11 participants will take Placebo,and calcium, and vitamin D (supplements) and in Year-2 they will crossover to Alendronate (study medication), calcium and vitamin D (supplements).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>12 Months Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Gr-1, lost followup; Gr-2, not compliant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>24 Months Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gr-1:Yr-1/Yr-2: Alendronate/Pbo, Calcium, Vitamin D</title>
          <description>Group-1/Year-1, 11 participants will take Alendronate,(study medication) and calcium, and vitamin D (supplements) and in Year-2 they will crossover to placebo, calcium and vitamin D supplements.</description>
        </group>
        <group group_id="B2">
          <title>Gr-2:Yr-1/Yr-2: Pbo/Alendronate, Calcium and Vitamin D</title>
          <description>Group-2/Year-1, 11 participants will take Placebo,and calcium, and vitamin D (supplements) and in Year-2 they will crossover to Alendronate (study medication), calcium and vitamin D (supplements).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.17" spread="2.8"/>
                    <measurement group_id="B2" value="9.47" spread="2.3"/>
                    <measurement group_id="B3" value="9.32" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Improvement in Bone Mineral Density (BMD) of Spine After Therapy</title>
        <description>Participants were screened for BMD of lumbar spine using DXA scan at visit 12 months after alendronate or placebo treatment.</description>
        <time_frame>12 months therapy</time_frame>
        <population>Analysis was done per protocol and intention to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Gr-1:Yr-1/Yr-2: Alendronate/Pbo, Calcium, Vitamin D</title>
            <description>Group-1/Year-1, 11 participants will take Alendronate,(study medication) and calcium, and vitamin D (supplements) and in Year-2 they will crossover to placebo, calcium and vitamin D supplements.</description>
          </group>
          <group group_id="O2">
            <title>Gr-2:Yr-1/Yr-2: Pbo/Alendronate, Calcium and Vitamin D</title>
            <description>Group-2/Year-1, 11 participants will take Placebo,and calcium, and vitamin D (supplements) and in Year-2 they will crossover to Alendronate (study medication), calcium and vitamin D (supplements).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Improvement in Bone Mineral Density (BMD) of Spine After Therapy</title>
          <description>Participants were screened for BMD of lumbar spine using DXA scan at visit 12 months after alendronate or placebo treatment.</description>
          <population>Analysis was done per protocol and intention to treat.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Improvement in Bone Mineral Density (BMD) of Hip After Therapy</title>
        <time_frame>12 months of therapy</time_frame>
        <population>Analysis was done per protocol and intention to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Gr-1:Yr-1/Yr-2: Alendronate/Pbo, Calcium, Vitamin D</title>
            <description>Group-1/Year-1, 11 participants will take Alendronate,(study medication) and calcium, and vitamin D (supplements) and in Year-2 they will crossover to placebo, calcium and vitamin D supplements.</description>
          </group>
          <group group_id="O2">
            <title>Gr-2:Yr-1/Yr-2: Pbo/Alendronate, Calcium and Vitamin D</title>
            <description>Group-2/Year-1, 11 participants will take Placebo,and calcium, and vitamin D (supplements) and in Year-2 they will crossover to Alendronate (study medication), calcium and vitamin D (supplements).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Improvement in Bone Mineral Density (BMD) of Hip After Therapy</title>
          <population>Analysis was done per protocol and intention to treat.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Improvement in Bone Mineral Density (BMD) of Spine After Therapy</title>
        <description>BMD of lumbar spine was measured using DXA scan at visit 24 months (Year-2)after alendronate or placebo treatment.</description>
        <time_frame>24 months therapy</time_frame>
        <population>Analysis was done per protocol and intention to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Gr-1:Yr-1/Yr-2: Alendronate/Pbo, Calcium, Vitamin D</title>
            <description>Group-1/Year-1, 11 participants will take Alendronate,(study medication) and calcium, and vitamin D (supplements) and in Year-2 they will crossover to placebo, calcium and vitamin D supplements.</description>
          </group>
          <group group_id="O2">
            <title>Gr-2:Yr-1/Yr-2: Pbo/Alendronate, Calcium and Vitamin D</title>
            <description>Group-2/Year-1, 11 participants will take Placebo,and calcium, and vitamin D (supplements) and in Year-2 they will crossover to Alendronate (study medication), calcium and vitamin D (supplements).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Improvement in Bone Mineral Density (BMD) of Spine After Therapy</title>
          <description>BMD of lumbar spine was measured using DXA scan at visit 24 months (Year-2)after alendronate or placebo treatment.</description>
          <population>Analysis was done per protocol and intention to treat.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Improvement in BMD of Hip</title>
        <description>Analysis was done per protocol and intention to treat.</description>
        <time_frame>24 months of therapy</time_frame>
        <population>Analysis was done per protocol and intention to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Gr-1:Yr-1/Yr-2: Alendronate/Pbo, Calcium, Vitamin D</title>
            <description>Group-1/Year-1, 11 participants will take Alendronate,(study medication) and calcium, and vitamin D (supplements) and in Year-2 they will crossover to placebo, calcium and vitamin D supplements.</description>
          </group>
          <group group_id="O2">
            <title>Gr-2:Yr-1/Yr-2: Pbo/Alendronate, Calcium and Vitamin D</title>
            <description>Group-2/Year-1, 11 participants will take Placebo,and calcium, and vitamin D (supplements) and in Year-2 they will crossover to Alendronate (study medication), calcium and vitamin D (supplements).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Improvement in BMD of Hip</title>
          <description>Analysis was done per protocol and intention to treat.</description>
          <population>Analysis was done per protocol and intention to treat.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Atraumatic Fractures</title>
        <description>Number of Participants with Atraumatic fractures before therapy.</description>
        <time_frame>0 months</time_frame>
        <population>Number of participants with fractures before therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Gr-1:Yr-1/Yr-2: Alendronate/Pbo, Calcium, Vitamin D</title>
            <description>Group-1/Year-1, 11 participants will take Alendronate,(study medication) and calcium, and vitamin D (supplements) and in Year-2 they will crossover to placebo, calcium and vitamin D supplements.</description>
          </group>
          <group group_id="O2">
            <title>Gr-2:Yr-1/Yr-2: Pbo/Alendronate, Calcium and Vitamin D</title>
            <description>Group-2/Year-1, 11 participants will take Placebo,and calcium, and vitamin D (supplements) and in Year-2 they will crossover to Alendronate (study medication), calcium and vitamin D (supplements).</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Atraumatic Fractures</title>
          <description>Number of Participants with Atraumatic fractures before therapy.</description>
          <population>Number of participants with fractures before therapy.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Atraumatic Fractures</title>
        <description>Number of participants with fractures at the completion of therapy.</description>
        <time_frame>24 months</time_frame>
        <population>Number of participants with fractures at study completion.</population>
        <group_list>
          <group group_id="O1">
            <title>Gr-1:Yr-1/Yr-2: Alendronate/Pbo, Calcium, Vitamin D</title>
            <description>Group-1/Year-1, 11 participants will take Alendronate,(study medication) and calcium, and vitamin D (supplements) and in Year-2 they will crossover to placebo, calcium and vitamin D supplements.</description>
          </group>
          <group group_id="O2">
            <title>Gr-2:Yr-1/Yr-2: Pbo/Alendronate, Calcium and Vitamin D</title>
            <description>Group-2/Year-1, 11 participants will take Placebo,and calcium, and vitamin D (supplements) and in Year-2 they will crossover to Alendronate (study medication), calcium and vitamin D (supplements).</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Atraumatic Fractures</title>
          <description>Number of participants with fractures at the completion of therapy.</description>
          <population>Number of participants with fractures at study completion.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>two years</time_frame>
      <desc>To make monthly phone calls to assess any side effects or adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Gr-1:Yr-1/Yr-2: Alendronate/Pbo, Calcium, Vitamin D</title>
          <description>Group-1/Year-1, 11 participants will take Alendronate,(study medication) and calcium, and vitamin D (supplements) and in Year-2 they will crossover to placebo, calcium and vitamin D supplements.</description>
        </group>
        <group group_id="E2">
          <title>Gr-2:Yr-1/Yr-2: Pbo/Alendronate, Calcium and Vitamin D</title>
          <description>Group-2/Year-1, 11 participants will take Placebo,and calcium, and vitamin D (supplements) and in Year-2 they will crossover to Alendronate (study medication), calcium and vitamin D (supplements).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Agreement with Merck: to submit a copy of any proposed abstract, manuscript and/or press release to Merck for review and comment at least 30 days prior to submission for publication or presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Deborah A Bowlby, MD, Asst.Professor, Pedeiatric Endocrinology</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-6807</phone>
      <email>bowlbyd@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

